{"id":"W2588138906","doi":"10.1093/ofid/ofw195.06","title":"Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection","year":2016,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Hepatitis C virus research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Theratechnologies (Canada)","funders":"","keywords":"Medicine; Clinical endpoint; Human immunodeficiency virus (HIV); Virology; Multiple drug resistance; Immunology; Pediatrics; Internal medicine; Drug resistance; Clinical trial; Microbiology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001931623,0.0002681646,0.0007004325,0.0003543449,0.0001936669,0.00003460457,0.0001428423,0.0000577251,0.0000651855],"category_scores_gemma":[0.0003164585,0.0001693452,0.0000763682,0.0004503919,0.0002674315,0.0003953791,0.0002242316,0.00008131927,0.000003437842],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005491088,"about_ca_system_score_gemma":0.0002362483,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01683796,"about_ca_topic_score_gemma":0.004984174,"domain_scores_codex":[0.9975483,0.0002384291,0.000800138,0.0005203466,0.0005091933,0.0003835346],"domain_scores_gemma":[0.9984902,0.0001803674,0.0003169832,0.0005861306,0.0002370295,0.0001893335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.020232,0.03111925,0.8866789,0.0000637062,0.0001417306,0.00002825172,0.001371033,0.00000501297,0.008514654,0.0000321197,0.0000138647,0.05179953],"study_design_scores_gemma":[0.08350432,0.02537578,0.8877208,0.0003382388,0.0001045876,0.00000170635,0.0002910594,0.00000655189,0.00227985,0.00001451222,0.0001749719,0.0001876128],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924203,0.00006893239,0.00001043745,0.00002735854,0.00002865994,0.003894559,0.0004965392,0.00003543043,0.003017773],"genre_scores_gemma":[0.9993225,0.0001684126,0.00001127072,0.00001441332,0.000006321161,0.0002750845,0.0001041766,0.00003334969,0.00006445947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06327232,"threshold_uncertainty_score":0.989709,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01850527196294311,"score_gpt":0.3390952722038267,"score_spread":0.3205900002408836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}